Emerging role of CAR T cells in Non-Hodgkin's Lymphoma Review uri icon

Overview

MeSH Major

  • Antigens, CD19
  • Immunotherapy, Adoptive
  • Neoplasms
  • T-Lymphocytes

abstract

  • Adoptive T-cell therapy with chimeric antigen receptor T cells (CAR-Ts) has produced impressive clinical responses among patients with B-cell malignancies, and several groups have published positive results using anti-CD19 CAR-Ts for the treatment of B-cell acute lymphoblastic leukemia. Recently, new data from clinical trials have demonstrated the benefits of CAR-T therapy in the non-Hodgkin's lymphoma (NHL) setting. This review describes some of the most recent and promising advances in engineered T-cell therapy, with particular emphasis on the clinical benefits of NHL treatment.

publication date

  • November 2017

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2017.7045

PubMed ID

  • 29118234

Additional Document Info

start page

  • 1429

end page

  • 1437

volume

  • 15

number

  • 11